ArticleActa neuropathologica2023
Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma.
Abstract readLetter
In one paragraph
Article in Acta neuropathologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- CDKN2A/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data.Acta neuropathologica communications · 2023Pooled it
- Comparative molecular profiles of distinct tumor components in recurrent tentorial meningioma after stereotactic radiosurgery: a case report implicating acquired aggressive alterations associated with WHO grade progression.Brain tumor pathology · 2026Article
- PD-L1 positivity predicts a unique hyperaggressive tumor group within MenG C meningiomas.JNCI cancer spectrum · 2026Article
- Development, validation, and utility of a clinically applicable methylation classifier for recurrence risk prediction in meningiomas.Acta neuropathologica communications · 2025Article
- Evolving Treatment Paradigms of Meningiomas; a Precision Medicine Perspective.Current neurology and neuroscience reports · 2025Review
- The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis.The Lancet. Oncology · 2025Article
- Pan-cancer copy number analysis identifies optimized size thresholds and co-occurrence models for individualized risk stratification.Nature communications · 2025Article
- NF2 loss-of-function and hypoxia drive radiation resistance in grade 2 meningiomas.Journal of the National Cancer Institute · 2025Article
- Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis.Neuro-oncology · 2025Article
- Refining prognostic stratification of atypical meningiomas: significance of chromosome 1p deletion and brain invasion.Acta neuropathologica communications · 2025Article
- cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.Neuro-oncology · 2025Review
- Molecular and histopathological landscape of 131 meningiomas: a retrospective institutional study with insights from cIMPACT-NOW.Frontiers in oncology · 2025Article
- Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.Neuro-oncology · 2024Review
- The Impact of Molecular and Genetic Analysis on the Treatment of Patients with Atypical Meningiomas.Diagnostics (Basel, Switzerland) · 2024Review
- Leveraging single-cell sequencing to classify and characterize tumor subgroups in bulk RNA-sequencing data.Journal of neuro-oncology · 2024Article
- Article
- Clinical implications of DNA methylation-based integrated classification of histologically defined grade 2 meningiomas.Acta neuropathologica communications · 2024Article
- The Evolving Classification of Meningiomas: Integration of Molecular Discoveries to Inform Patient Care.Cancers · 2024Review
- Gene transcript fusions are associated with clinical outcomes and molecular groups of meningiomas.Acta neuropathologica · 2024Article
- Atypical meningioma: Histopathological, genetic, and epigenetic features to predict recurrence risk.Histology and histopathology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
A Basit Khan *Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
Collin W English *Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
William C ChenDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Prazwal AthukuriDepartment of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0001-7239-8618
James C BayleyDepartment of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0002-1959-4625
Vicky L BrandtJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX, USA.ORCID 0000-0002-5512-3724
Arya ShettyDepartment of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
Caroline C HadleyDepartment of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0001-9575-2608
Abrar ChoudhuryDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-8312-2457
Hsiang-Chih LuJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX, USA.ORCID 0000-0002-4927-4577
Arif O HarmanciCenter for Secure Artificial Intelligence For hEalthcare (SAFE), Center for Precision Health, School of Biomedical Informatics, University of Texas Health Science Center Houston, Houston, TX, USA.ORCID 0000-0002-9696-1118
Akdes S HarmanciDepartment of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0001-6374-9041
Stephen T MagillDepartment of Neurological Surgery, Northwestern University, Chicago, IL, USA.ORCID 0000-0002-5257-7835
David R RaleighDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-9299-8864
Tiemo J Klisch *Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX, USA. klisch@bcm.edu.ORCID 0000-0001-8182-384X
Akash J Patel *Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA. akash.patel@bcm.edu.ORCID 0000-0002-1280-2989
Funding
Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6MUnderstanding druggable drivers of meningioma tumorigenesisR01CA262311 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RALEIGH, DAVID R · 2021 to 2025
$2.7MBaylor Research Education Program in NeurosurgeryR25NS070694 · NINDS · BAYLOR COLLEGE OF MEDICINE · PI SHETH, SAMEER ANIL · 2010 to 2023
$1.2MEstablishing the Genomic Landscape of Human Atypical MeningiomasK08NS102474 · NINDS · BAYLOR COLLEGE OF MEDICINE · PI PATEL, AKASH J. · 2017 to 2021
$869kInvestigating the Regulation and Role of FOXM1 in Aggressive MeningiomaF30CA246808 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOUDHURY, ABRAR · 2020 to 2023
$159kDevelopment of a molecular diagnostic and prognostic signature for meningiomaF32CA213944 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MAGILL, STEPHEN T · 2017 to 2017
$63kNCI NIH HHS F30 CA246808NCI NIH HHS F32 CA213944NCI NIH HHS P50 CA097257NCI NIH HHS R01 CA262311NIGMS NIH HHS T32 GM007618NINDS NIH HHS K08 NS102474NINDS NIH HHS R25 NS070694
Abstract
PubMed holds no abstract for this paper.
Indexed as
Meningeal NeoplasmsMeningiomaCyclin-Dependent Kinase Inhibitor p16HumansNeoplasm Recurrence, LocalCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.